208 related articles for article (PubMed ID: 34982509)
21. S309-CAR-NK cells bind the Omicron variants
Ma MT; Jiang Q; Chen C-H; Badeti S; Wang X; Zeng C; Evans D; Bodnar B; Marras SAE; Tyagi S; Bharaj P; Yehia G; Romanienko P; Hu W; Liu S-L; Shi L; Liu D
J Virol; 2024 Jun; 98(6):e0003824. PubMed ID: 38767356
[TBL] [Abstract][Full Text] [Related]
22. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
[TBL] [Abstract][Full Text] [Related]
24. Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy.
Inal JM
Clin Sci (Lond); 2020 Jun; 134(12):1301-1304. PubMed ID: 32542396
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
[TBL] [Abstract][Full Text] [Related]
26. Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants.
Li M; Chen J; Liu Y; Zhao J; Li Y; Hu Y; Chen YQ; Sun L; Shu Y; Feng F; Sun C
Antiviral Res; 2022 Sep; 205():105383. PubMed ID: 35917969
[TBL] [Abstract][Full Text] [Related]
27. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy.
Xie F; Su P; Pan T; Zhou X; Li H; Huang H; Wang A; Wang F; Huang J; Yan H; Zeng L; Zhang L; Zhou F
Adv Mater; 2021 Dec; 33(49):e2103471. PubMed ID: 34665481
[TBL] [Abstract][Full Text] [Related]
28. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.
Sheikhi A; Hojjat-Farsangi M
Hum Vaccin Immunother; 2021 Jan; 17(1):92-97. PubMed ID: 32663051
[TBL] [Abstract][Full Text] [Related]
29. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
[TBL] [Abstract][Full Text] [Related]
30. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.
Mou H; Quinlan BD; Peng H; Liu G; Guo Y; Peng S; Zhang L; Davis-Gardner ME; Gardner MR; Crynen G; DeVaux LB; Voo ZX; Bailey CC; Alpert MD; Rader C; Gack MU; Choe H; Farzan M
PLoS Pathog; 2021 Apr; 17(4):e1009501. PubMed ID: 33836016
[TBL] [Abstract][Full Text] [Related]
31. Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity.
Havranek B; Chan KK; Wu A; Procko E; Islam SM
J Chem Inf Model; 2021 Sep; 61(9):4656-4669. PubMed ID: 34427448
[TBL] [Abstract][Full Text] [Related]
32. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
[TBL] [Abstract][Full Text] [Related]
33. Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2
Kober DL; Caballero Van Dyke MC; Eitson JL; Boys IN; McDougal MB; Rosenbaum DM; Schoggins JW
mBio; 2024 Jun; 15(6):e0076824. PubMed ID: 38771062
[TBL] [Abstract][Full Text] [Related]
34. Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant.
Cianfarini C; Hassler L; Wysocki J; Hassan A; Nicolaescu V; Elli D; Gula H; Ibrahim AM; Randall G; Henkin J; Batlle D
Cells; 2024 Jan; 13(3):. PubMed ID: 38334597
[TBL] [Abstract][Full Text] [Related]
35. Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species.
Zhang HL; Li YM; Sun J; Zhang YY; Wang TY; Sun MX; Wang MH; Yang YL; Hu XL; Tang YD; Zhao J; Cai X
J Biol Chem; 2021; 296():100435. PubMed ID: 33610551
[TBL] [Abstract][Full Text] [Related]
36. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.
Tanaka S; Nelson G; Olson CA; Buzko O; Higashide W; Shin A; Gonzalez M; Taft J; Patel R; Buta S; Richardson A; Bogunovic D; Spilman P; Niazi K; Rabizadeh S; Soon-Shiong P
Sci Rep; 2021 Jun; 11(1):12740. PubMed ID: 34140558
[TBL] [Abstract][Full Text] [Related]
37. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.
Zhang L; Narayanan KK; Cooper L; Chan KK; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
bioRxiv; 2022 Mar; ():. PubMed ID: 35378764
[TBL] [Abstract][Full Text] [Related]
38. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM
J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
[TBL] [Abstract][Full Text] [Related]
40. Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
Wang Q; Ye SB; Zhou ZJ; Li JY; Lv JZ; Hu B; Yuan S; Qiu Y; Ge XY
J Med Virol; 2023 Jan; 95(1):e28116. PubMed ID: 36056469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
